Funding Search - Pivot

The University of Vermont, through Sponsored Project Administration (SPA) subscribes to Pivot, a web-based funding search tool. The UVM Cancer Center has collaborated with SPA to create a customized cancer relevant pivot search. Press the button for Cancer Funding Opportunities.

Cancer Funding Opportunities

If you would prefer to set up your own pivot search and automated alerts you can learn more about pivot HERE.

For Pivot Assistance

Please review the information provided by SPA

Hilda Alajajian, Grant Resources Specialist is available to meet with individuals or groups for assistance in identifying funding

Phone: (802)656-1322

Should you learn of an opportunity not listed here but important to UVM Cancer Center research, please contact Laura Gordon.


Limited Competition Funding

Please contact Edward North for information on applying for Limited Funding Opportunities. 

Peer-Reviewed Funding Sources

Below is a list of fund sources from federal agencies, non-profit foundations and regional and national organizations to support cancer research are provided below for UVM Cancer Center researchers. This of funding is considered NCI approved peer-reviewed funding and can also be found in PDF format at the following link: NCI Peer-Reviewed Fund Sources


  1. Agency for Healthcare Research and Quality (AHRQ)
  2. Alex’s Lemonade Stand Foundation (ALSF)
  3. American Association of Cancer Research (AACR)
  4. American Cancer Society (ACS) (national office only)
  5. American Foundation for AIDS Research (amfAR)
  6. American Institute for Cancer Research (AICR)
  7. California Institute for Regenerative Medicine (CIRM)
  8. Cancer Prevention Research Institute of Texas (CPRIT)
  9. Center for Disease Control and Prevention (CDC)
  10. Central Office of the Veterans Administration (VA) (excluding local/regional & “block” grants)
  11. Environmental Protection Agency (EPA)
  12. The Flight Attendant Medical Research Institute (FAMRI)
  13. Florida Biomedical Research Program (FBRP)
  14. Food and Drug Administration (FDA)
  15. Howard Hughes Medical Institute (HHMI)
  16. Leukemia and Lymphoma Society (LLS)
  17. Melanoma Research Alliance (MRA)
  18. Multiple Myeloma Research Foundation (MMRF)
  19. National Institute for Occupational Safety and Health (NIOSH)
  20. National Science Foundation (NSF)
  21. New York State Department of Health Wadsworth Center/New York State Stem Cell Science Program (NYSTEM)
  22. Patient-Centered Outcomes Research Institute (PCORI)
  23. Prevent Cancer Foundation (PCF)
  24. Prostate Cancer Foundation (PCF)
  25. Susan G. Komen for the Cure
  26. The California Breast Cancer Research Program (CBCRP)
  27. The California Tobacco Related Disease Research Program (TRDRP)
  28. U.S. Army (DOD) special research programs *

Highlights: New & Updated

New and Updated
Joint Catalyst Award The Gund Institute for Environment at The University of Vermont (UVM), the UVM Larner College of Medicine, and the Maine Medical Center Research Institute are joining forces to offer a $100,000 award for research at the intersection of rural health and the natural environment. 

The collaboration is aimed at better understanding how environmental concerns relate to human health. The Gund Institute and the Northern New England Clinical and Translational Research Network (NNE-CTR) are the co-conveners of this Joint Catalyst Award.

Proposals are due by April 30, 2020. The award period will begin July 1, 2020 and end August 31, 2022.

 

Prostate Cancer Foundation - 2020 PCF Challenge Awards For Metastatic, Lethal Prostate Cancer - "The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. High risk, currently unfunded projects are most desired.

PCF Challenge Awards:

  • Composed of a team of at least three (3) investigators from non-profit academic research centers, including one young investigator (see PCF Challenge Award Team requirements below).
  • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of two years.
  • Provide up to a total of $1 million per team.
  • Cover only direct research costs and travel to the Annual PCF Scientific Retreat.
Clinical trial costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at time of application."

 

Apply online here: https://pcf.smartsimple.com accepting applications beginning Wednesday, February 5, 2020.

Deadline: Friday, April 17,2020, 3:00 pm EDT

Department of Defense (DoD) Breast Cancer Research Program (BCRP)-

BreakthroughAward Levels 1 and 2 - "The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:
Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.
Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. The Government reserves the right to fund an application at a lower funding level."

Deadline: March 26, 2020

Department of Defense (DoD) Breast Cancer Research Program (BCRP)- BreakthroughAward Level 3 -"The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact:
Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.
Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. The Government reserves the right to fund an application at a lower funding level."

Deadline: June 24, 2020

Department of Defense (DoD) Breast Cancer Research Program (BCRP)- BreakthroughAward Level 4 -"The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:
Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.
Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. The Government reserves the right to fund an application at a lower funding level."

Deadline: June 24, 2020

Department of Defense (DoD) Breast Cancer Research Program (BCRP)- Era of Hope Scholar Award -"The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:
Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.
Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. The Government reserves the right to fund an application at a lower funding level."

Deadline: March 26, 2020

Department of Defense (DoD) Breast Cancer Research Program (BCRP)- Innovator Award -"The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:
Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.
Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. The Government reserves the right to fund an application at a lower funding level."

Deadline: June 24, 2020

NIH - PAR-18-951 "Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)" - "The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health.  It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).

Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting clinical research projects in collaboration with NIH intramural investigators."

Application Due: April 15, 2020